| This article has been cited by |
| 1 | Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis | |
| Wael A. Alghamdi,Abdullah Alsultan,Mohammad H. Al-Shaer,Guohua An,Shahriar Ahmed,Yosra Alkabab,Sayera Banu,Ketevan Barbakadze,Eric Houpt,Maia Kipiani,Lali Mikiashvili,Stephan Schmidt,Scott K. Heysell,Russell R. Kempker,J. Peter Cegielski,Charles A. Peloquin |
| Antimicrobial Agents and Chemotherapy.2019;63(5) |
| [DOI] |
|
| 2 | Neuropsychiatric Effects of Antimicrobial Agents | |
| Nicholas Zareifopoulos,George Panayiotakopoulos |
| Clinical Drug Investigation.2017;37(5)423 |
| [DOI] |
|
| 3 | Cycloserine | |
| Nicholas Zareifopoulos,George Panayiotakopoulos |
| Reactions Weekly.2016;1588(1)95 |
| [DOI] |
|
| 4 | Cycloserine | |
| M. Smith,A. Accinelli,F.R. Tejada,M.K. Kharel |
| Reactions Weekly.2016;38(1)283 |
| [DOI] |
|
| 5 | Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis | |
| Zubair Shanib Bhat,Muzafar Ahmad Rather,Mubashir Maqbool,Hafiz UL Lah,Syed Khalid Yousuf,Zahoor Ahmad |
| Biomedicine & Pharmacotherapy.2017;95(1)1520 |
| [DOI] |
|
| 6 | Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon | |
| Zubair Shanib Bhat,Muzafar Ahmad Rather,Mubashir Maqbool,Zahoor Ahmad |
| Biomedicine & Pharmacotherapy.2018;103(1)1733 |
| [DOI] |
|
